help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2004-1393
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
146/7/2942    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cvetkovic, I.
Right arrow Articles by Stosic-Grujicic, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cvetkovic, I.
Right arrow Articles by Stosic-Grujicic, S.
Endocrinology Vol. 146, No. 7 2942-2951
Copyright © 2005 by The Endocrine Society

Critical Role of Macrophage Migration Inhibitory Factor Activity in Experimental Autoimmune Diabetes

Ivana Cvetkovic, Yousef Al-Abed, Djordje Miljkovic, Danijela Maksimovic-Ivanic, Jesse Roth, Michael Bacher, Hui Y. Lan, Ferdinando Nicoletti and Stanislava Stosic-Grujicic

Institute for Biological Research Sinisa Stankovic (I.C., D.M., D.M.-I., S.S.-G.), 11000 Belgrade, Serbia and Montenegro; New York University School of Medicine (Y.A.-A.), New York, New York 10016; Laboratory of Medicinal Chemistry, North Shore Long Island Jewish Health System (Y.A.-A.), Manhasset, New York 11030; Department of Geriatric, North Shore Long Island Jewish Health System (J.R.), New York, New York 11040; Department of Neurology (M.B.), University of Bonn, 10016 Bonn, Germany; Department of Medicine-Nephrology, Baylor College of Medicine (H.Y.L.), Houston, Texas 77030; and Department of Biomedical Sciences, University of Catania (F.N.), Catania 95021, Italy

Address all correspondence and requests for reprints to: Dr. Yousef Al-Abed, New York School of Medicine, North Shore Long Island Jewish Research Institute, 350 Community Drive, Manhasset, New York 11030. E-mail: yalabed{at}nshs.edu. Or to: Dr. Stanislava Stosic-Grujicic, Institute for Biological Research Sinisa Stankovic, 29 Novembra 142, 11000 Belgrade, Serbia and Montenegro. E-mail: duta{at}eunet.yu.

Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that plays a pivotal role in several immunoinflammatory and autoimmune diseases. In this study we examined the role of MIF in the development of immunoinflammatory diabetes induced in susceptible strains of mice by multiple low doses of streptozotocin. We found that MIF protein was significantly elevated in islet cells during the development of diabetes, and that targeting MIF activity with either neutralizing antibody or the pharmacological inhibitor (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester, markedly reduced clinical and histopathological features of the disease, such as hyperglycemia and insulitis. Lymphocytes from mice treated with the MIF inhibitors exhibited reduction of both islet antigen-specific proliferative responses and adhesive cell-cell interactions. Neutralization of MIF also down-regulated the ex vivo secretion of the proinflammatory mediators, TNF-{alpha}, interferon-{gamma}, and nitric oxide, while augmenting that of the antiinflammatory cytokine, IL-10. This study provides the first in vivo evidence for a critical role for MIF in the immune-mediated ß-cell destruction in an animal model of human type 1 diabetes mellitus and identifies a new therapeutic strategy for the prevention and treatment of this disease in humans that is based on the selective inhibition of MIF activity.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
G. V. Crichlow, K. F. Cheng, D. Dabideen, M. Ochani, B. Aljabari, V. A. Pavlov, E. J. Miller, E. Lolis, and Y. Al-Abed
Alternative Chemical Modifications Reverse the Binding Orientation of a Pharmacophore Scaffold in the Active Site of Macrophage Migration Inhibitory Factor
J. Biol. Chem., August 10, 2007; 282(32): 23089 - 23095.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Stosic-Grujicic, I. Cvetkovic, K. Mangano, M. Fresta, D. Maksimovic-Ivanic, L. Harhaji, D. Popadic, M. Momcilovic, D. Miljkovic, J. Kim, et al.
A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxasole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptozotocin in CBA/H Mice
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1038 - 1049.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
D. Aeberli, M. Leech, and E. F. Morand
Macrophage migration inhibitory factor and glucocorticoid sensitivity
Rheumatology, August 1, 2006; 45(8): 937 - 943.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Al-Abed, D. Dabideen, B. Aljabari, A. Valster, D. Messmer, M. Ochani, M. Tanovic, K. Ochani, M. Bacher, F. Nicoletti, et al.
ISO-1 Binding to the Tautomerase Active Site of MIF Inhibits Its Pro-inflammatory Activity and Increases Survival in Severe Sepsis
J. Biol. Chem., November 4, 2005; 280(44): 36541 - 36544.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society